Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.
This prospective and open-label study evaluates the efficacy and safety of mFOLFIRINOX as postoperative chemotherapy in treating Chinese patients with pancreatic cancer after R0/R1 resection.
Pancreatic Cancer Resectable
DRUG: mFOLFORINOX
Regression Free Survival, defined as the period from the date of resection to tumor relapse caused by any reason, Up to 24 months
Overall Survival, the duration from enrollment to the patient's death (all causes), Up to 24 months
adverse events and severe adverse events, number of patients with adverse events and severity according to NCI Common Toxicity Criteria(CTC) 3.0, Up to 12 weeks|EORTC Quality of Life Questionnaire(QLQ)-C30, Quality of life will be assessed at each study using EORTC QLQ-C30, Up to 24 weeks
The patients will be treated with systemic FOLFIRINOX chemotherapy of adjusted dosage.